vascuCAP vs ElucidVivo A.3
AI Verdict
Choose vascuCAP if…
Choose vascuCAP (now ElucidVivo/PlaqueIQ) if your primary need is a comprehensive cardiovascular risk assessment that includes the quantification of intraplaque hemorrhage. This tool is ideal for optimizing treatment decisions by providing a broad, histologically-validated characterization of plaque composition to stratify patients for stroke and heart attack risk.
View vascuCAP →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if your focus is on detailed atherosclerosis patient stratification and assessing plaque stability, particularly when the derivation of fractional flow reserve (FFRct) is a critical component of your diagnostic workflow. This system excels in providing granular, lesion-level plaque composition analysis and 3D visualization to guide precise treatment strategies.
View ElucidVivo A.3 →When choosing between vascuCAP (now ElucidVivo/PlaqueIQ) and ElucidVivo A.3, physicians should consider their specific needs for cardiovascular risk assessment and treatment optimization. Both tools, developed by Elucid Bioimaging, are FDA-cleared AI software designed for non-invasive CT angiography analysis, quantifying plaque composition, and aiding in treatment decisions. They share core functionalities such as AI-enabled CT angiogram analysis, 3D visualization of arterial vessels and plaque, and the quantification of various plaque components like lipid-rich necrotic core and calcification. Both also integrate with DICOM and offer PACS/EMR interoperability, with deployment options including cloud and on-premise.
The key practical difference lies in their stated feature sets. While vascuCAP emphasizes risk stratification for stroke and heart attack and support for personalized treatment decisions, ElucidVivo A.3 explicitly highlights its ability to derive fractional flow reserve (FFRct) based on vessel wall vasodilative capacity. This suggests that ElucidVivo A.3 may offer a more in-depth physiological assessment of coronary lesions beyond just plaque morphology. Therefore, a physician primarily focused on comprehensive risk stratification and general plaque characterization for broad treatment decisions might lean towards vascuCAP. In contrast, a physician seeking more advanced physiological insights, particularly FFRct derivation for a deeper understanding of lesion hemodynamics, would find ElucidVivo A.3 to be the more suitable choice.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | vascuCAP | ElucidVivo A.3 |
|---|---|---|
| Pricing | Contact for pricing | Contact for pricing |
| Deployment | Cloud and on-premise | Software application, likely on-premise or cloud-based (standard for medical imaging software, not explicitly detailed, but integrates with PACS/EMR). |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
TieBoth tools are from the same company, and ElucidVivo A.3 is a direct evolution of vascuCAP, suggesting a consistent user experience. Both offer 3D visualization and integrate with existing PACS/EMR systems, which are key for clinical usability. While ElucidVivo A.3 mentions 'rotatable curved MPR vessel views,' this is likely a refinement rather than a fundamental difference in overall usability.
Clinical Value
ElucidVivo A.3Both tools offer strong clinical value through histologically-validated plaque quantification and risk stratification. However, ElucidVivo A.3 (Tool B) explicitly includes the derivation of fractional flow reserve (FFRct) based on vessel wall vasodilative capacity, which provides an additional, valuable metric for assessing lesion-specific ischemia and further optimizing treatment decisions. Furthermore, there are indications of improved histological validation methods in the newer iteration.
Pricing & Value
TieBoth tools explicitly state 'contact for pricing,' indicating a lack of public pricing transparency. As they are from the same company and represent a continuous product line, their pricing structures are likely similar, making it impossible to distinguish their value proposition without specific cost details.
Enterprise Readiness
TieBoth tools are FDA-cleared and integrate with PACS/EMR systems, which are crucial for enterprise adoption. While Tool A explicitly states HIPAA compliance and BAA availability, Tool B, as the rebranded and updated version of Tool A, is expected to maintain these same high standards for data security and regulatory adherence for healthcare use.
Innovation
ElucidVivo A.3Both tools are highly innovative for their AI-powered, histology-validated plaque quantification. However, ElucidVivo A.3 (Tool B) demonstrates further innovation by incorporating the derivation of fractional flow reserve (FFRct) for non-invasive ischemia assessment, which is a significant advancement in cardiovascular diagnostics. Additionally, it has refined its histological validation methods, indicating continuous improvement.
Support & Docs
TieThe provided information and web search results do not offer specific details regarding the type, quality, or availability of customer support and documentation for either tool. As both products originate from Elucid Bioimaging and are part of the same product evolution, it is reasonable to assume they share a common support infrastructure.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | vascuCAP | ElucidVivo A.3 |
|---|---|---|
| Name | vascuCAP (now ElucidVivo/PlaqueIQ) | ElucidVivo A.3 |
| Company | Elucid Bioimaging | Elucid Bioimaging |
| Tagline | AI-enabled software for precise cardiovascular diagnostic imaging and plaque assessment. | AI-Powered Plaque Analysis for Cardiovascular Care |
| Plaque Quantification Details | Quantification of lipid-rich necrotic core, calcification, non-calcified matrix, intraplaque hemorrhage; Histologically-validated plaque quantification and characterization. | Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images; Validated on ground-truth histology. |
| Visualization | 3D visualization of arterial vessels and plaque | Visualizes lesion-level plaque composition; Provides 3D visualization of highlighted vessels; Offers rotatable curved MPR vessel views and cross-sections. |
Videos
Demos, reviews, and walkthroughs featuring vascuCAP and ElucidVivo A.3.